Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Enzon Pharmaceuticals Inc (NASDAQ:ENZN)

1.37
Delayed Data
As of Jul 31
 -0.01 / -0.72%
Today’s Change
0.78
Today|||52-Week Range
1.88
+38.51%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$60.5M

Company Description

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company. The company engages in the research and development of innovative therapeutics for cancer patients with high unmet medical needs. Its drug-development programs utilize two platforms such as customized PEGylation linker technology and third-generation mRNA-targeting agents utilizing the locked nucleic acid technology. The company receives royalties on marketed products that utilize PEGylation platform, including PegIntron, Sylatron, Macugen, CIMZIA, OMONTYS, Oncaspar and Adagen. Enzon Pharmaceuticals was founded by Abraham Abuchowski on September 17, 1981 and is headquartered in Piscataway, NJ.

Contact Information

Enzon Pharmaceuticals, Inc.
20 Kingsbridge Road
Piscataway New Jersey 08854
P:(732) 980-4500
Investor Relations:

Employees

Shareholders

Mutual fund holders7.40%
Other institutional43.59%
Individual stakeholders23.18%

Top Executives

George W. HebardChief Executive Officer, COO & Secretary
Richard L. FeinsteinChief Financial Officer & Vice President